Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 8Breast Neoplasms 5Stomach Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Colonic Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Fluorouracil 67Radiotherapy 53Cisplatin 52Oxaliplatin 47Leucovorin 37Paclitaxel 36Irinotecan 27Docetaxel 23Capecitabine 20Nivolumab 17Carboplatin 16pembrolizumab 15Radiation 15Neoadjuvant Therapy 15Surgical Procedures, Operative 12Cetuximab 12durvalumab 9Drug Therapy 9Biopsy 9Taxes 8Folfox protocol 8Chemotherapy, Adjuvant 8Trastuzumab 7Magnetic Resonance Spectroscopy 7Gefitinib 7Endoscopy 7tremelimumab 6Specimen Handling 6Endoscopy, Digestive System 6Ramucirumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × tucatinib × Gastrointestinal × Clear all
NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Seagen Inc.

Phase 2 Active not recruiting
40 enrolled 67 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04499924 2025-01-22

MOUNTAINEER-02

Seagen Inc.

Phase 2/3 Completed
17 enrolled 23 charts
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡